Published in Eur J Haematol on April 07, 2014
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med (2012) 4.15
Microarray results: how accurate are they? BMC Bioinformatics (2002) 3.23
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci U S A (2008) 2.60
STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood (2012) 2.55
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
How I treat LGL leukemia. Blood (2010) 2.38
T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. Leuk Lymphoma (2011) 2.37
Large granular lymphocyte leukemia. Oncologist (2006) 2.21
Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res (2011) 2.10
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol (2013) 2.07
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood (2013) 1.80
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood (2012) 1.67
The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders. Hematol Oncol (2010) 1.67
Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control (2014) 1.67
Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano (2011) 1.63
Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol (2012) 1.61
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood (2013) 1.59
ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene (2004) 1.56
Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem (2012) 1.53
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol (2010) 1.53
Dynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia. PLoS Comput Biol (2011) 1.51
Clinical features of large granular lymphocyte leukemia. Semin Hematol (2003) 1.50
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program (2012) 1.45
Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood (2008) 1.45
Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy (2011) 1.44
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood (2005) 1.34
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol (2014) 1.34
Antigen activation and impaired Fas-induced death-inducing signaling complex formation in T-large-granular lymphocyte leukemia. Blood (2007) 1.32
NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest (2011) 1.30
Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res (2013) 1.24
Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther (2011) 1.22
Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw (2013) 1.20
Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. Blood (2011) 1.20
Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev (2006) 1.19
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol (2014) 1.18
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood (2009) 1.17
Pathogenesis, diagnosis, and management of Kikuchi-Fujimoto disease. Cancer Control (2014) 1.15
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol (2010) 1.14
Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk (2010) 1.12
Congenital and acquired neutropenia. Hematology Am Soc Hematol Educ Program (2004) 1.10
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res (2010) 1.10
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood (2010) 1.09
Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood (2004) 1.09
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer (2012) 1.08
miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood (2013) 1.08
A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood (2008) 1.07
Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am J Surg Pathol (2003) 1.07
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2011) 1.06
Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia. Blood (2002) 1.05
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett (2009) 1.04
Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol (2003) 1.04
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood (2011) 1.03
Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw (2012) 1.03
Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. Int J Oncol (2005) 1.02
Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res (2009) 1.02
The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol (2011) 1.01
Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk (2011) 0.98
HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy. J Biol Chem (2012) 0.98
Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res (2007) 0.98
Survival signals in leukemic large granular lymphocytes. Semin Hematol (2003) 0.97
Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control (2007) 0.96
Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood (2008) 0.96
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma (2015) 0.95
Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol (2007) 0.95
Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control (2014) 0.94
Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw (2014) 0.94
Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control (2007) 0.94
Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. Future Oncol (2012) 0.93
Large granular lymphocyte leukemia. Curr Hematol Malig Rep (2007) 0.92
Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol (2003) 0.92
Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim Biophys Acta (2002) 0.92
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs (2014) 0.90
Diseases of large granular lymphocytes. Cancer Control (2007) 0.89
Skeletal muscle peripheral T-cell lymphoma. J Clin Oncol (2008) 0.89
Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw (2016) 0.89
Liver injury during acute pancreatitis: the role of pancreatitis-associated ascitic fluid (PAAF), p38-MAPK, and caspase-3 in inducing hepatocyte apoptosis. J Gastrointest Surg (2003) 0.88
The effect of selenium enrichment on baker's yeast proteome. J Proteomics (2011) 0.88
Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med (2014) 0.87
Microarray, gene sequencing, and reverse transcriptase-polymerase chain reaction analyses of a cryptic PML-RARA translocation. Cancer Genet (2012) 0.87
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A (2013) 0.87
Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control (2014) 0.86
Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res (2004) 0.86
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol (2013) 0.86
Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control (2014) 0.85
Three cases of isolated terminal deletion of chromosome 8p without heart defects presenting with a mild phenotype. Am J Med Genet A (2013) 0.85
Galaxy tools to study genome diversity. Gigascience (2013) 0.84
Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol (2013) 0.83
A review of large granular lymphocytic leukemia in Fischer 344 rats as an initial step toward evaluating the implication of the endpoint to human cancer risk assessment. Toxicol Sci (2007) 0.83
Erythropoietin receptor signaling is membrane raft dependent. PLoS One (2012) 0.83
Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant. Transplantation (2004) 0.82